FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to 1,4-substituted piperazines or 4-alkyledinyl piperidines of the general formula (I):
and its geometric isomers, enantiomers, diastereomers and pharmaceutically salts wherein G and G' in common form:
, 
or 
;
D means -CH= or =N-; Y means -L2-V(Z)t-L3- wherein t means 0 or 1; W means -N(OM)C(O)N(R8)R9. Compounds elicit both property to inhibit leukotriene and anti-histaminergic properties and can be used in treatment of asthma, season and chronic allergic rhinitis. Also, invention describes a pharmaceutical composition based on compounds of the formula (I) and a method for treatment.
EFFECT: improved treatment method, valuable medicinal properties of compounds.
22 cl, 9 dwg, 5 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LYSINE-SPECIFIC HISTONE DEMETHYLASE 1A (KDM1A) INHIBITORS FOR DISEASE THERAPY | 2019 |
|
RU2813145C2 |
| CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM | 2018 |
|
RU2795146C2 |
| 2-OXA-5-AZABICYCLO[2.2.1]HEPTANE-3-YL DERIVATIVES | 2015 |
|
RU2697651C2 |
| SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | 2014 |
|
RU2671212C2 |
| 1-(4-ISOXAZOLE-5-YL)-1H-PYRAZOLE-1-YL)-2-METHYLPROPANE-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-17 AND IFN-GAMMA INHIBITORS FOR TREATMENT OF AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | 2018 |
|
RU2785342C2 |
| NOVEL AMMONIUM DERIVATIVES, A METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2016 |
|
RU2743098C2 |
| NOVEL DERIVATIVES OF ACETAMIDE, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION AND PROTEASE INHIBITORS BASED ON THEREOF | 1997 |
|
RU2181360C2 |
| PYRAZINONE DERIVATIVES AND USE THEREOF IN TREATMENT OF LUNG DISEASES | 2008 |
|
RU2479580C2 |
| N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR TREATING CANCER | 2005 |
|
RU2427572C2 |
| APOPTOSIS INDUCING AGENTS SELECTIVE FOR Bcl-2 FOR CANCER AND IMMUNE DISEASES TREATMENT | 2013 |
|
RU2621052C2 |
